Arch Biopartners Inc's stock remains under pressure despite recent developments in its clinical trials.
This week, Arch Biopartners Inc (ARCH.V) saw a slight decline in its stock price, ending the week down 0.97%. While the company has made strides in its clinical trials, the market reaction has been muted.
Advertisement
Arch Biopartners Inc
ARCH.V
ARCH.V
Arch Biopartners Inc
WealthAwesomeMarket cap
$69.29M
52W high
$1.68
52W low
$0.39
1W change
-0.97%
Beta
1.72
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARCH's historical volatility
30-Day Vol
103.5%
Annualized
90-Day Vol
107.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$1.22
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.08 | C$0.76 – C$1.55 |
| 60 trading days | C$1.15 | C$0.69 – C$1.90 |
| 90 trading days | C$1.22 | C$0.66 – C$2.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the recent developments in Arch Biopartners' clinical trials as potential long-term catalysts, but should also remain cautious given the stock's recent performance and the overall volatility associated with small-cap biotech stocks.
Arch Biopartners Inc's stock is currently priced at C$1.05, down 18.40% YTD.
The stock's 52-week range of C$0.39 to C$1.68 indicates significant volatility, which is typical in the biotech sector.
Bull case
The approval for U.S. site expansion in Arch Biopartners' Phase II trial could boost its visibility and funding opportunities, potentially enhancing its long-term prospects.
Bear case
The company's stock has struggled this year, and the lack of immediate news or significant market interest could continue to pressure its price.
Price Action Overview
Advertisement
Arch Biopartners Inc's stock closed at C$1.05, showing no change on the day but a decline of 0.97% over the week. Year-to-date, the stock has decreased by 18.40%. This performance highlights the challenges faced by small-cap biotech firms in the current market environment.
Recent Developments
Arch Biopartners recently received central Institutional Review Board approval for its Phase II trial of LSALT peptide, aimed at addressing cardiac surgery-associated acute kidney injury. This approval is significant as it allows for the trial's expansion into the U.S., following interest from multiple leading institutions. However, despite this positive news, the stock has not seen a corresponding uptick in price, indicating cautious investor sentiment.
Technical Picture
The technical indicators for ARCH.V show a last close of C$1.05, with a 50-day moving average at C$0.95 (+10.9% vs price) and a 200-day moving average at C$0.85 (+23.3% vs price). The stock's 52-week range is C$0.39 to C$1.68, suggesting that it is currently trading at 51% of its range. The beta of 1.72 indicates higher volatility compared to the market, which is typical for biotech stocks. Recent trading volume of 8,143 shares is significantly below the 20-day average volume of 62,164 shares, reflecting reduced investor interest.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
